A study presented at UEG Week 2020 suggests a minimally-invasive, outpatient procedure combined with GLP-1 RA therapy could help diabetics eliminate the need for insulin therapy.
Metformin is the first-line drug that can lower blood sugar levels in type 2 diabetes patients. One third of patients do not respond to metformin treatment and 5 per cent experience serious side effects, which is the reason many choose to stop medicating. Researchers at Lund University in Sweden have now identified biomarkers that can show in advance how the patient will respond to metformin treatment via a simple blood test.
Slow-release molecule featuring two complementary type 2 diabetes drugs controls blood sugar levels while promoting weight loss in mice for one week following a single injection
Early signs of being more susceptible to type 2 diabetes as an adult can be seen in children as young as 8 years old, decades before it is likely to be diagnosed, according to a new study published in Diabetes Care.
It is estimated that 7.3% of the global adult population has some alterations in their metabolism resulting in hyperglycemia, an increase in blood sugar, not to the range we determine is diabetes, but heading in that direction, the individual with “prediabetes.”
Intermittent fasting is known to improve sensitivity to the blood glucose-lowering hormone insulin and to protect against fatty liver. DZD scientists from DIfE have now discovered that mice on an intermittent fasting regimen also exhibited lower pancreatic fat. In their current study published in the journal Metabolism, the researchers showed the mechanism by which pancreatic fat could contribute to the development of type 2 diabetes.